A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma
Our real-world experience confirms the high rate of durable objective responses, good tolerability and long treatment duration of cemiplimab in elderly and frail cSCC patients as well.
Authors
- Maura Colucci (ORCID: https://orcid.org/0000-0003-4069-9330)
- Vincenzo D’Alonzo (ORCID: https://orcid.org/0000-0002-9264-377X)
- Michele Maio
- Giovanni Rubino
- Clelia Miracco (ORCID: https://orcid.org/0000-0001-7642-7404)
- Matteo Ravara
- Tijjani Sani
- Luca Grimaldi (ORCID: https://orcid.org/0000-0002-9251-4396)
- Olindo Massarelli (ORCID: https://orcid.org/0000-0001-7674-0134)
- Roberto Cuomo
- Valentina Croce
- Eleonora Carbonari
- Ramiz Rana
- Monica Valente
- Pietro Rubegni
- Elisa Cinotti
- Anna Maria Di Giacomo
Institutions
- University of Siena (IT)
- Agostino Gemelli University Polyclinic (IT)
Publication Details
- Journal
- Cancers
- Published
- 2026-01-30
- DOI
- https://doi.org/10.3390/cancers18030454
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00